These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

221 related items for PubMed ID: 10785238

  • 1. A pilot study involving minimal ovarian stimulation for in vitro fertilization: extending the "follicle-stimulating hormone window" combined with the gonadotropin-releasing hormone antagonist cetrorelix.
    de Jong D, Macklon NS, Fauser BC.
    Fertil Steril; 2000 May; 73(5):1051-4. PubMed ID: 10785238
    [Abstract] [Full Text] [Related]

  • 2. Dynamics of the development of multiple follicles during ovarian stimulation for in vitro fertilization using recombinant follicle-stimulating hormone (Puregon) and various doses of the gonadotropin-releasing hormone antagonist ganirelix (Orgalutran/Antagon).
    de Jong D, Macklon NS, Eijkemans MJ, Mannaerts BM, Coelingh Bennink HJ, Fauser BC, Ganirelix Dose-Finding Study Group.
    Fertil Steril; 2001 Apr; 75(4):688-93. PubMed ID: 11287020
    [Abstract] [Full Text] [Related]

  • 3. A randomized comparison of two ovarian stimulation protocols with gonadotropin-releasing hormone (GnRH) antagonist cotreatment for in vitro fertilization commencing recombinant follicle-stimulating hormone on cycle day 2 or 5 with the standard long GnRH agonist protocol.
    Hohmann FP, Macklon NS, Fauser BC.
    J Clin Endocrinol Metab; 2003 Jan; 88(1):166-73. PubMed ID: 12519847
    [Abstract] [Full Text] [Related]

  • 4. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment.
    Beckers NG, Macklon NS, Eijkemans MJ, Ludwig M, Felberbaum RE, Diedrich K, Bustion S, Loumaye E, Fauser BC.
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4186-92. PubMed ID: 12970285
    [Abstract] [Full Text] [Related]

  • 5. Early luteal phase endocrine profile is affected by the mode of triggering final oocyte maturation and the luteal phase support used in recombinant follicle-stimulating hormone-gonadotropin-releasing hormone antagonist in vitro fertilization cycles.
    Fatemi HM, Polyzos NP, van Vaerenbergh I, Bourgain C, Blockeel C, Alsbjerg B, Papanikolaou EG, Humaidan P.
    Fertil Steril; 2013 Sep; 100(3):742-7. PubMed ID: 23806846
    [Abstract] [Full Text] [Related]

  • 6. Recombinant follicle-stimulating hormone and recombinant luteinizing hormone versus recombinant follicle-stimulating hormone alone during GnRH antagonist ovarian stimulation in patients aged ≥35 years: a randomized controlled trial.
    Vuong TN, Phung HT, Ho MT.
    Hum Reprod; 2015 May; 30(5):1188-95. PubMed ID: 25740882
    [Abstract] [Full Text] [Related]

  • 7. Recombinant luteinizing hormone supplementation to recombinant follicle-stimulating hormone induced ovarian hyperstimulation in the GnRH-antagonist multiple-dose protocol.
    Griesinger G, Schultze-Mosgau A, Dafopoulos K, Schroeder A, Schroer A, von Otte S, Hornung D, Diedrich K, Felberbaum R.
    Hum Reprod; 2005 May; 20(5):1200-6. PubMed ID: 15665010
    [Abstract] [Full Text] [Related]

  • 8. Comparison of luteal phase profile in gonadotrophin stimulated cycles with or without a gonadotrophin-releasing hormone antagonist.
    Ragni G, Vegetti W, Baroni E, Colombo M, Arnoldi M, Lombroso G, Crosignani PG.
    Hum Reprod; 2001 Nov; 16(11):2258-62. PubMed ID: 11679500
    [Abstract] [Full Text] [Related]

  • 9. Revival of the natural cycles in in-vitro fertilization with the use of a new gonadotrophin-releasing hormone antagonist (Cetrorelix): a pilot study with minimal stimulation.
    Rongières-Bertrand C, Olivennes F, Righini C, Fanchin R, Taïeb J, Hamamah S, Bouchard P, Frydman R.
    Hum Reprod; 1999 Mar; 14(3):683-8. PubMed ID: 10221695
    [Abstract] [Full Text] [Related]

  • 10. Basal serum progesterone and history of elevated progesterone on the day of hCG administration are significant predictors of late follicular progesterone elevation in GnRH antagonist IVF cycles.
    Venetis CA, Kolibianakis EM, Bosdou JK, Lainas GT, Sfontouris IA, Tarlatzis BC, Lainas TG.
    Hum Reprod; 2016 Aug; 31(8):1859-65. PubMed ID: 27301360
    [Abstract] [Full Text] [Related]

  • 11. Minimal stimulation IVF with late follicular phase administration of the GnRH antagonist cetrorelix and concomitant substitution with recombinant FSH: a pilot study.
    Pelinck MJ, Vogel NE, Hoek A, Arts EG, Simons AH, Heineman MJ.
    Hum Reprod; 2005 Mar; 20(3):642-8. PubMed ID: 15608031
    [Abstract] [Full Text] [Related]

  • 12. Effectiveness of cetrorelix for the prevention of premature luteinizing hormone surge during controlled ovarian stimulation using letrozole and gonadotropins: a randomized trial.
    Lee TH, Lin YH, Seow KM, Hwang JL, Tzeng CR, Yang YS.
    Fertil Steril; 2008 Jul; 90(1):113-20. PubMed ID: 18054932
    [Abstract] [Full Text] [Related]

  • 13. Follicular phase endocrine characteristics during ovarian stimulation and GnRH antagonist cotreatment for IVF: RCT comparing recFSH initiated on cycle day 2 or 5.
    Blockeel C, Sterrenburg MD, Broekmans FJ, Eijkemans MJ, Smitz J, Devroey P, Fauser BC.
    J Clin Endocrinol Metab; 2011 Apr; 96(4):1122-8. PubMed ID: 21307142
    [Abstract] [Full Text] [Related]

  • 14. The luteal phase of recombinant follicle-stimulating hormone/gonadotropin-releasing hormone antagonist in vitro fertilization cycles during supplementation with progesterone or progesterone and estradiol.
    Fatemi HM, Camus M, Kolibianakis EM, Tournaye H, Papanikolaou EG, Donoso P, Devroey P.
    Fertil Steril; 2007 Mar; 87(3):504-8. PubMed ID: 17140572
    [Abstract] [Full Text] [Related]

  • 15. Results with early follicular phase recombinant luteinizing hormone supplementation during stimulation for in vitro fertilization.
    Kovacs P, Kovats T, Kaali SG.
    Fertil Steril; 2010 Feb; 93(2):475-9. PubMed ID: 19200991
    [Abstract] [Full Text] [Related]

  • 16. Initiation of ovarian stimulation independent of the menstrual cycle: a case-control study.
    Buendgen NK, Schultze-Mosgau A, Cordes T, Diedrich K, Griesinger G.
    Arch Gynecol Obstet; 2013 Oct; 288(4):901-4. PubMed ID: 23545834
    [Abstract] [Full Text] [Related]

  • 17. [Effect of domestic highly purified urinary follicle stimulating hormone on outcomes of in vitro fertilization-embryo transfer in controlled ovarian stimulation].
    Ye H, Huang GN, Cao YX, Zhong Y, Huang YH, Zhu GJ, Zhou LM, Chen ZJ, Shi JZ, Zeng Y, Weng N, Huang XF, Yang J, Zhu YM, Li YP, Yi D, Zhuang GL.
    Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):838-42. PubMed ID: 24444561
    [Abstract] [Full Text] [Related]

  • 18. A mild ovarian stimulation strategy in women with poor ovarian reserve undergoing IVF: a multicenter randomized non-inferiority trial.
    Youssef MA, van Wely M, Al-Inany H, Madani T, Jahangiri N, Khodabakhshi S, Alhalabi M, Akhondi M, Ansaripour S, Tokhmechy R, Zarandi L, Rizk A, El-Mohamedy M, Shaeer E, Khattab M, Mochtar MH, van der Veen F.
    Hum Reprod; 2017 Jan; 32(1):112-118. PubMed ID: 27836979
    [Abstract] [Full Text] [Related]

  • 19. Daily low-dose hCG stimulation during the luteal phase combined with GnRHa triggered IVF cycles without exogenous progesterone: a proof of concept trial.
    Andersen CY, Elbaek HO, Alsbjerg B, Laursen RJ, Povlsen BB, Thomsen L, Humaidan P.
    Hum Reprod; 2015 Oct; 30(10):2387-95. PubMed ID: 26209535
    [Abstract] [Full Text] [Related]

  • 20. Comparison of different doses of gonadotropin-releasing hormone antagonist Cetrorelix during controlled ovarian hyperstimulation.
    Albano C, Smitz J, Camus M, Riethmüller-Winzen H, Van Steirteghem A, Devroey P.
    Fertil Steril; 1997 May; 67(5):917-22. PubMed ID: 9130900
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.